AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01360840
Drug: EMD 525797
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
Trial: NCT00016913
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=6 week one of each 4 week cycle
Trial: NCT00016913
Drug: estramustine
RxNorm normalized name: Estramustine
DrugBank: Estramustine (DB01196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets tid PO 5 of 7 days per week each 4 week cycle
Trial: NCT00016913
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
Trial: NCT00016913
Drug: leuprolide or goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg IM injection once every 4 weeks for 6 months
Trial: NCT00067639
Drug: Pegfilgrastim (Neulasta)
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 mg single injection of pegfilgrastim under the skin prior to apheresis.
Trial: NCT01263470
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00224588
Drug: Ketamine (or placebo : isotonic saline solution)
RxNorm normalized name: ketamine Injectable Solution
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01263470
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT01263470
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Trial: NCT00437203
Drug: PF-00477736
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion.
Trial: NCT00437203
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
Trial: NCT00396058
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00297323
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 patients over the age of 2 years old with epilepsy.
Trial: NCT00728091
Drug: Satavaptan
RxNorm normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01888224
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin Capsules,40 mg
Trial: NCT00292955
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
Trial: NCT03997760
Drug: TAK-755
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
Trial: NCT01674192
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose of 2 mg prucalopride
Trial: NCT01521572
Drug: Salbutamol sulphate
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
Trial: NCT03137017
Drug: GRT7014 - Abuse Deterrent Tablet
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose in one of the four cross-over trial periods.
Trial: NCT01313182
Drug: 3M Skin and Nasal Antiseptic
RxNorm normalized name: 3M Skin and Nasal Antiseptic
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
Trial: NCT01263470
Drug: Voglibose
RxNorm normalized name: Voglibose
DrugBank: Voglibose (DB04878)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Trial: NCT01695317
Drug: Acetyl-L-carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
Trial: NCT00630513
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 days regimen with Ertapenem (1 g/day i.v.)
Trial: NCT00630513
Drug: Ampicillin-Sulbactam
RxNorm normalized name: ampicillin-sulbactam
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
Trial: NCT00291811
Drug: AMD3100 + G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
Trial: NCT01134575
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
Trial: NCT00015457
Drug: Amlodipine plus Botulinum toxin
RxNorm normalized name: Botulinum toxin type A
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02616367
Drug: liposomal bupivacaine Periarticular injection
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine used for a periarticular injection in the knee
Trial: NCT02616367
Drug: Ropivacaine Periarticular Injection
RxNorm normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular Injection for the knee with ropivacaine
Trial: NCT04312568
Drug: Fadanafil
RxNorm normalized name: Avanafil
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Trial: NCT00198172
Drug: Cisplatin plus Epirubicin
RxNorm normalized name: Cisplatin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01700790
Drug: Lopinavir/ritonavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
Trial: NCT01724788
Drug: FUROSEMIDE
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: Intravenous
Trial: NCT01724788
Drug: FUROSEMIDE (HOE058)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT00000456
Drug: naltrexone (Revia)
RxNorm normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04260009
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib tablets
Trial: NCT04260009
Drug: Brigatinib AAF
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib age-appropriate formulation (AAF)
Trial: NCT00420589
Drug: taranabant
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
Trial: NCT03015831
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine will be given to open heart surgery patients
Trial: NCT04220944
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
Trial: NCT00094809
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Trial: NCT00638755
Drug: Nasal Carbon Dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal Carbon Dioxide
Trial: NCT00100659
Drug: Pegylated Interferon/ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00390403
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03006081
Drug: Intravitreal Aflibercept injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
Trial: NCT04593836
Drug: L-menthol
RxNorm normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Trial: NCT01378299
Drug: Testosterone Cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61.
Trial: NCT01873807
Drug: VP-16
RxNorm normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-16: 15mg/kg, -2d, -1d
Trial: NCT02322216
Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02322216
Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.1%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02322216
Drug: Olopatadine 0.2% Vehicle
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as placebo comparator
Trial: NCT00317655
Drug: Ginger
RxNorm normalized name: Ginger
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317655
Drug: Ginger-Avocado-Soya
RxNorm normalized name: Avocado
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00034151
Drug: S-8184 Paclitaxel Injectable Emulsion
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00933868
Drug: Magnesium Chloride
RxNorm normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
Trial: NCT02124681
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
Trial: NCT02172378
Drug: Tiotropium inhalation capsules
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00538889
Drug: Lecozotan SR
RxNorm normalized name: Lecozotan
DrugBank: Lecozotan (DB12540)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00538889
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04066803
Drug: MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
Trial: NCT01407900
Drug: CD-NP
RxNorm normalized name: CD-NP
DrugBank: Cenderitide (DB11777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-NP as a four hour infusion at 10 ng/kg/min IV
Trial: NCT01407900
Drug: 5% Dextrose in Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four hour infusion IV
Trial: NCT00004898
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01738555
Drug: amdoxovir 300 mg bid
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg capsules bid
Trial: NCT01738555
Drug: amdoxovir 500 mg bid
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 250 mg capsules bid
Trial: NCT00140881
Drug: MK0476; montelukast sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076492
Drug: CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076492
Drug: GPI 1485
RxNorm normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01672788
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin tablets and metformin tablet
Trial: NCT01672788
Drug: Empagliflozin + Metformin
RxNorm normalized name: empagliflozin / metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fixed dose combination tablet (low)
Trial: NCT01672788
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: empagliflozin tablets and metformin tablet
Trial: NCT01672788
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: empagliflozin tablet and metformin tablet
Trial: NCT01672788
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin tablet and metformin tablet
Trial: NCT01493557
Drug: pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg q.a.m, p.o.
Trial: NCT01493557
Drug: Pradaxa (dabigatran etexilate)
RxNorm normalized name: Pradaxa
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
Trial: NCT00966966
Drug: SAM-531 and gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
Trial: NCT01628042
Drug: Vibegron 100 mg
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron tablets, orally, on Day 1
Trial: NCT01347632
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
Trial: NCT01602289
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01602289
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02750709
Drug: Nitisinone
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
Trial: NCT02750709
Drug: Nitisinone 10 mg Tablet High Compritol
RxNorm normalized name: nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
Trial: NCT02750709
Drug: Orfadin
RxNorm normalized name: Orfadin
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
Trial: NCT01356225
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
Trial: NCT04271007
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mometasone furoate
Trial: NCT00254878
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04309357
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
Trial: NCT02702674
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propranolol 20 mg given before induction of labor
Trial: NCT02702674
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of oxytocin
Trial: NCT03152149
Drug: Tiotropium & olodaterol
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
Trial: NCT03152149
Drug: fluticasone furoate & vilanterol
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
Trial: NCT01636206
Drug: Lifitegrast
RxNorm normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
Trial: NCT00578617
Drug: Rate Control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50-100mg
Trial: NCT00578617
Drug: Rate Control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100mg,
Trial: NCT00578617
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 40-80mg
Trial: NCT00578617
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol 200mg
Trial: NCT00578617
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25mg
Trial: NCT00578617
Drug: Rate Control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem 180-240mg
Trial: NCT00578617
Drug: Rate Control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil 180-240mg